Evidence map›Paper›PMID 42481780›Full record

Articlenpj drug discovery2026

Prioritizing neuroactive ligands using motif-guided virtual discovery and zebrafish profiling.

Ari B Ginsparg, Jaqueline A Martinez, Ishaan Patel, Angélique Buton, Laura T Lee, Raheel Sarwar, Rocco Moretti, Stephanie Puig, Summer B Thyme

Abstract read
In one paragraph

Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ari B GinspargDepartment of Neurobiology, The University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, USA.
Jaqueline A MartinezDepartment of Biochemistry and Molecular Biotechnology, UMass Chan Medical School, Worcester, MA, USA.
Ishaan PatelDepartment of Computational Biology, University of Pennsylvania, Philadelphia, PA, USA.
Angélique ButonDepartment of Psychiatry and Behavioral Sciences, UMass Chan Medical School, Worcester, MA, USA.
Laura T LeeDepartment of Biochemistry and Molecular Biotechnology, UMass Chan Medical School, Worcester, MA, USA.
Raheel SarwarDepartment of Biochemistry and Molecular Biotechnology, UMass Chan Medical School, Worcester, MA, USA.
Rocco MorettiDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA.
Stephanie PuigDepartment of Psychiatry and Behavioral Sciences, UMass Chan Medical School, Worcester, MA, USA.
Summer B ThymeDepartment of Neurobiology, The University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, USA. Summer.Thyme@umassmed.edu.

Funding

Defining the Chemical Perturbome of Neural Development and ActivityDP2NS132107 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI THYME, SUMMER B · 2022 to 2025
$2.3M
NIH HHS DP2 NS132107NINDS NIH HHS DP2 NS132107
6 · The paper itself

Abstract

Virtual screening of ultra-large chemical libraries is a highly effective strategy for early-stage ligand discovery. However, these pipelines often yield thousands of molecules that pass computational filters, and in silico-derived interaction energies do not consistently predict experimental efficacy. Furthermore, many high-affinity hits do not necessarily function effectively in an organism with tissues, barriers, and extensive off-target possibilities. Here, we establish and apply an integrated pipeline that prioritizes candidate molecules through structure-guided computation and zebrafish-based functional profiling. We introduce Rosetta Engine for Anchoring Ligands with a Motif ("REAL-M"), a screening algorithm that uses structural interaction data from the Protein Data Bank (PDB) to guide ligand placement and selection. Using the hypocretin receptor as a test case, 28 of 30 predicted antagonists significantly blocked binding of the cognate peptide agonist in a cell-based reporter assay, including six chemically diverse molecules with efficacy comparable to preexisting antagonists. Three of these six significantly mitigated hypocretin-induced larval zebrafish hyperactivity. Secondary testing with a zebrafish hcrtr2 null mutant ensured that behavioral phenotypes were on target, in contrast to off-target phenotypes observed with a clinically approved antagonist. This pipeline is readily adaptable to the thousands of zebrafish proteins with highly conserved binding pockets.

Identifiers

PMID42481780
PMCPMC13389409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.